PMCF Study on the Safety, Performance and Clinical Benefits Data of the Anatomical Shoulder 2.0 Fracture System
Key facts
- Where
- Salamanca, SpainSee the site
Where in Spain
- Salamenca University HospitalSalamanca, SpainContact: Alberto Moreno, DrTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Zimmer Biomet
- Trial code
- NCT05351112
- Record updated
- 17 August 2025
- Original description
The study is a multicenter, retrospective and prospective, non-randomized, non-controlled and consecutive series post-market study. The purpose of this study is to collect long-term data confirming safety, performance and clinical benefits of the Anatomical Shoulder 2.0 Fracture System (Implants and Instrumentation) when used for fracture shoulder arthroplasty. The primary objective is the assessment of safety by analyzing implant survivorship. This will be established by recording the incidence and frequency of revisions, complications and adverse events. Relation of the events to implant, instrumentation and/or procedure should be specified.Read full original descriptionShow less
Post-market Clinical Follow-up Study to Provide Safety, Performance and Clinical Benefits Data of the Anatomical Shoulderᵀᴹ 2.0 Fracture System (Implants and Instrumentation) - A Retrospective and Prospective Consecutive Series Study
The study is a multicenter, retrospective and prospective, non-randomized, non-controlled and consecutive series post-market study. The purpose of this study is to collect long-term data confirming safety, performance and clinical benefits of the Anatomical Shoulder 2.0 Fracture System (Implants and Instrumentation) when used for fracture shoulder arthroplasty. The primary objective is the assessment of safety by analyzing implant survivorship. This will be established by recording the incidence and frequency of revisions, complications and adverse events. Relation of the events to implant, instrumentation and/or procedure should be specified.
The secondary objective is the assessment of performance and clinical benefits by recording patient-reported clinical outcome measures (PROMs) as well as radiographic outcomes.
Inclusion: Patients 18 years or older and skeletally mature; Patients capable of understanding the surgeon's explanations and following his instructions, able and willing to participate in the follow-up program and who gave consent to take part in the study; Replacement of the proximal humerus and the glenoid articular surface of the scapula during total-, hemi- and fracture shoulder arthroplasty in treatment of the following:; Complex 3- and 4- part fractures of the proximal humerus with subluxation of the head fragment; Complex 3- and 4- part fractures of the proximal humerus with loosening of the spongiosa in the head fragment; Complex 3- and 4- part fractures of the proximal humerus with additional cross split of the head fragment; Fracture instability after osteosynthesis of 3- and 4-part fracture fragments of the proximal humerus; Posttraumatic necrosis of the humeral head; Posttraumatic arthrosis after humeral head fracture.
Exclusion: Patient is a vulnerable subject (prisoner, mentally incompetent or unable to understand what participation to the study entails, a known alcohol or drug abuser, anticipated to be non-compliant); Patients who have any condition that would in the judgment of the Investigator place the patient at undue risk or interfere with the study; Signs of infection; Patients who are unwilling or unable to give consent, not willing to return for study required follow-up visits and/or to comply with the follow-up program; The patient is known to be pregnant or breastfeeding; Patients with plans to relocate during the study follow-up period; Extensive stiffening of the shoulder joint without pain.